A Guide To Ischemic Optic Neuropathy
Ischemic optic neuropathy is an eye condition that affects the optic nerve. It occurs when a blockage prevents blood flow to the optic nerve. This can cause vision loss or impairment.
The optic nerve, which is at the back of the eye, sends messages about what a person sees from the eye to the brain. Ischemic optic neuropathy happens when a blockage stops blood flow to this nerve.
Blood carries nutrients and oxygen to the optic nerve. Without blood flow, the optic nerve no longer works. This results in a loss of vision. Ischemic optic neuropathy can happen in one or both eyes.
This article explains what ischemic optic neuropathy is, including its symptoms, causes, and treatment options.
Ischemic optic neuropathy occurs when blood can no longer reach the optic nerve. This damages the optic nerve and can cause vision loss. Depending on the location of the blockage, doctors mainly refer to this condition as either anterior or posterior ischemic optic neuropathy.
Anterior ischemic optic neuropathy (AION) has two subtypes — arteritic and non-arteritic ischemic optic neuropathy — based on the cause of damage.
Arteritic ischemic optic neuropathy occurs due to inflammation in the optic nerve. This can result from a condition called giant cell arteritis.
Non-arteritic ischemic optic neuropathy is the more common type. It occurs when there is another cause of blocked blood flow to the optic nerve. Several factors can increase a person's risk. Anything that can damage blood vessels increases the risk of damage to the optic nerve.
All types of ischemic optic neuropathy lead to a lack of blood flow and serious damage to the optic nerve.
Posterior ischemic optic neuropathy (PION) is less common than AION. Experts believe that PION is the result of a blockage of the blood supply to the retrobulbar optic nerve. PION differs from AION in that the optic nerve head appears typical. This makes PION challenging to diagnose.
Before ischemic optic neuropathy develops, a person may experience vision loss. This vision loss is usually painless but can develop quickly, sometimes within minutes, hours, or days.
If a person has giant cell arteritis, they may also experience:
Anyone who experiences sudden vision loss should contact a healthcare professional. A person should also seek medical attention if they experience brief periods of vision loss. These episodes can be a symptom of impaired blood flow to the optic nerve, which increases the risk of ischemic optic neuropathy.
Anyone who has risk factors for ischemic optic neuropathy should check in regularly with a primary care doctor and an eye specialist.
There are several risk factors for developing ischemic optic neuropathy. Anything that impairs blood flow in the body can affect blood flow to the optic nerve.
Most cases of AION are non-arteritic. The risk factors include:
Giant cell arteritis can cause arteritic ischemic optic neuropathy. The risk of developing giant cell arteritis is highest in white women aged 70–80 years.
An eye specialist, usually an ophthalmologist, can diagnose ischemic optic neuropathy.
To make the diagnosis, an ophthalmologist will dilate a person's pupils. This allows the ophthalmologist to get a better view of the optic nerve.
The specialist will look for changes in blood flow, damage to blood vessels, and changes in the optic nerve. The optic nerve will appear swollen upon examination in people with ischemic optic neuropathy.
A doctor may also order blood work to look for signs of inflammation that may indicate giant cell arteritis.
If giant cell arteritis is the cause of a person's ischemic optic neuropathy, the person may take oral or injected steroid medication. Steroids can quickly reduce inflammation to prevent further vision loss. This can also help prevent vision loss in the other eye.
There is no proven way to fully restore vision in any type of ischemic optic neuropathy. If the condition has affected only one eye, the goal is to prevent vision loss in the other eye. The best strategy is to manage any risk factors.
Once a person develops ischemic optic neuropathy, vision loss is typically permanent in the affected eye. In some cases, a person may still have some peripheral (side) vision. Some people may find that their vision comes back after they start prompt steroid treatment.
Follow-up with an eye specialist is important. If the condition has occurred in only one eye, it is possible to prevent vision loss in the other eye, mainly by managing risk factors.
Ischemic optic neuropathy has many risk factors, and prevention is not always possible. Screening for risk factors and managing them can help prevent damage to the optic nerve.
Depending on a person's risk factors, strategies for preventing ischemic optic neuropathy may include:
Regular follow-up with an optometrist or ophthalmologist is important. An eye specialist can monitor a person's eye health and identify any signs of damage early.
Ischemic optic neuropathy occurs when a blockage prevents blood flow to the optic nerve. This can damage the nerve and cause vision loss. The condition has several risk factors. People can manage their risk factors to prevent damage to the optic nerve.
It is important for a person who is at risk for ischemic optic neuropathy to check in regularly with an eye specialist. Vision loss from this condition is typically permanent. It may be possible to prevent vision loss in the other eye after a person receives a diagnosis of ischemic optic neuropathy.
Healthy Colorado: New Treatment For Ischemic Strokes At UCHealth
COLORADO SPRINGS, Colo. (KRDO) -- Every minute counts when having a stroke. And now, UCHealth hospitals across Colorado have begun treating patients experiencing acute ischemic stroke with a medication that is faster and simpler to administer. Which are both key during a stroke.
Ischemic strokes are the most common type and are usually caused by a blood clot that blocks or plugs a blood vessel into the brain.
The clot-busting medication Tenecteplase, also known as TNK is now being used in place of Alteplase, or tPA, which had been the standard for nearly three decades in treating strokes. Though both medications break up clots and restore blood flow in the brain, TNK is considerably easier to administer.
According to a press release from UCHealth, this medicine switch will require fewer steps, which leads to less opportunity for delays and errors.
Strokes are the fifth leading cause of death in the United States, according to the American Stroke Association. They are also a major cause of long-term disability, with deficits ranging from the inability to recognize people to immobility and language impairment.
Medications to treat ischemic strokes must be given within 4.5 hours of the onset of symptoms. Unfortunately, too many patients are waiting too long to get help and are thus not eligible for such life-saving and disability-preventing medications, according to doctors.
It is critical to know the signs of stroke, as symptoms are often sudden and many doctors refer to time as the brain when one does happen.
Use the letters B.E. F.A.S.T to spot a stroke:
B = Balance/difficulty standing or walking
E = Sudden changes in eyesight, such as loss of vision or double vision
F = Facial drooping
A = Arm weakness
S = Speech difficulty
T = Time to call 911
Vertebrobasilar Artery Syndrome Treatment Market Demand, Trends And Analysis Research Report Till 2030
(MENAFN- America News Hour) Research Nester published a report titled"vertebrobasilar artery syndrome treatment market : Global Demand Analysis & Opportunity Outlook 2030" which delivers detailed overview of theglobalvertebrobasilar artery syndrome treatment market in terms of market segmentation by diagnosis, treatment, distribution channel, and by region.Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The globalvertebrobasilar artery syndrome treatment market is anticipated to attain a notable CAGR over the forecast period, i.E., 2022 – 2030. The market is segmented on the basis of treatment into surgery and medication, among which, the medication segment is anticipated to hold the largest share in the market over the forecast period owing to the lower cost, and easier administration of drugs. Moreover, the risk involved with bypass surgeries is another factor estimated to promote the demand for medication as the treatment for vertebrobasilar artery syndrome.
Download Sample of This Strategic Report@
The globalvertebrobasilar artery syndrome treatment market is estimated to grow on the back of increasing prevalence of lifestyle diseases and poor healthcare habits, in majority of the population, along with rising geriatric population of the world. The primary cause of vertebrobasilar artery syndrome is the deposition of plaque made of cholesterol and calcium in the arteries, which narrows or even blocks the arteries. This prevents the flow of blood to the back of the brain. The poor lifestyle, including habits like smoking and drinking, increases the risk of vertebrobasilar artery syndrome, which is estimated to boost the market growth.
On the basis of geographical analysis, the global vertebrobasilar artery syndrome treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to gain significant growth during the forecast period on account of developing healthcare infrastructure and improving medical facilities in developing nations. Moreover, rising geriatric population in the countries, such as, India and China, is estimated to boost the market growth.As per the data by the World Bank,11.96% of the total population of China was above 65 years, in 2020.
The research was global in nature and conducted in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa). In addition, areas like Market size, Y-O-Y growth & Opportunity Analysis, market players competitive study, investment opportunities, demand for future outlook etc. Have been covered and displayed in the research report to ensure it dives deep to achieve strategic competitive intelligence in the segment.
Do You Have Any Query Or Specific Requirement? Ask to Our Expert:
Rising Global Geriatric Population to Boost the Market Growth
According to the statistics by the World Bank, the global geriatric population, i.E., population aged above 64 years crossed 722,133,150 in 2020, which is 9.318% of the total global population.
Vertebrobasilar artery syndrome is common in older adults owing to the higher levels of LDL or bad cholesterol in their bodies. This is why, the growing geriatric population is estimated to have a positive influence on the market growth. Moreover, increasing health awareness amongst the population is also estimated to boost the market growth.
"The Final Report will cover the impact analysis of COVID-19 on this industry."
However, lack of health awareness amongst people is expected to operate as key restraint to the growth of the global vertebrobasilar artery syndrome treatment market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global vertebrobasilar artery syndrome treatment market which includes company profiling of Merck & Co., Inc., Siemens Healthcare GmbH, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., Baxter International, Inc., Novartis AG, Sanofi-aventis Groupe, Pfizer, Inc., and AbbVie Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global vertebrobasilar artery syndrome treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Read More Information@
About Research Nester
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
AJ Daniel
Email:
U.S. Phone: +1 646 586 9123
MENAFN17032023004545010068ID1105801009
Legal Disclaimer:MENAFN provides the information "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
Post a Comment